HCPCS code J3471 – Hyaluronidase ovine injection

Key takeaways

HCPCS code J3471 covers preservative-free ovine hyaluronidase (Vitrase), while bovine products bill under J3470 and recombinant Hylenex under J3473.

Bill J3471 per 1 USP unit administered, for doses up to 999 units.

Doses of 1,000 units or more go on J3472 per 1,000 units, with any remainder under 1,000 on J3471.

Most payers require the 11-digit NDC on every J3471 line, and a missing NDC is a leading denial trigger.

J3471 always pairs with an administration code, such as CPT 96372 for an injection or 96369 for a subcutaneous infusion.

HCPCS code J3471: Descriptor, code type, and quick-reference data

HCPCS code J3471 is a permanent Level II drug code maintained by the Centers for Medicare and Medicaid Services (CMS). It covers preservative-free ovine hyaluronidase, billed per 1 USP unit for doses up to 999 units. Vitrase is the product billed under it. Larger ovine doses move to J3472, and bovine and recombinant products have codes of their own.

J3471 appears in the current CMS HCPCS Level II file as an active, permanent code. Vitrase is the main commercially available product billed under it. The source of the enzyme is what separates J3471 from J3470, the code for bovine hyaluronidase such as Amphadase and Hydase. Billing J3470 for a Vitrase administration is a coding error.

Drug overview: Hyaluronidase ovine (Vitrase) and its FDA-approved indications

Hyaluronidase ovine is an enzyme derived from ovine (sheep) testicular tissue. It temporarily breaks down hyaluronic acid in connective tissue, increasing the absorption and diffusion of co-administered substances. The FDA-approved indications for Vitrase decide which ICD-10 diagnosis codes support medical necessity on J3471 claims.

• Adjuvant to increase absorption of other injected drugs: hyaluronidase is added to subcutaneous or intramuscular injections to speed drug dispersion.
• Hypodermoclysis: subcutaneous fluid administration, typically for patients with difficult IV access, such as elderly or pediatric patients.
• Subcutaneous urography: an adjuvant to improve resorption of radiopaque agents when IV administration is not feasible.

Off-label uses, including cosmetic filler dissolution, are generally not covered by Medicare or Medicaid under J3471. Document the FDA-approved indication when establishing medical necessity. Vitrase’s preservative-free formulation matters clinically for patients sensitive to preservatives. In the code set, though, the line between J3471 and J3470 is the enzyme’s source, ovine rather than bovine.

J3471 unit billing: Calculating units from the administered dose

J3471 bills per 1 USP unit of hyaluronidase administered, for doses up to 999 USP units. Doses of 1,000 units or more are billed with J3472, the per-1,000-unit code, with any remainder under 1,000 on J3471. Check payer policy, since some payers set their own rules for that split.

Bill the quantity administered, not the total contents of the vial. Coders often submit vial-level quantities, which is where most unit errors start. When a single-dose vial holds more than the dose given, the unused portion is waste. Report it with modifier JW on a separate line, covered in detail below.

J3471 vs J3470, J3472 and J3473: Choosing the correct code

Four HCPCS codes cover hyaluronidase, and each maps to a distinct source or dose range. Picking the wrong one is a common J3471 error, and a modifier cannot fix it. The claim line has to be rebilled with the correct code.

The deciding factor is the product dispensed and administered. Vitrase is J3471 up to 999 units, and J3472 per 1,000 units above that. A bovine product such as Amphadase or Hydase is J3470, and Hylenex, the recombinant product, is J3473. When the chart doesn’t name the product, query the provider rather than defaulting to J3470 as a catch-all. The diagram below maps each product and dose to its code.

NDC reporting requirements for J3471 claims

Medicare Part B and most state Medicaid programs require an NDC alongside HCPCS code J3471, and commercial payers commonly do too. A missing or malformed NDC is a leading cause of J3471 rejection at the clearinghouse, often before the claim reaches the payer. Track NDC fields at the point of superbill documentation so the information is captured before billing.

How to format the NDC on a J3471 claim

1. Use the 11-digit NDC format in the 5-4-2 configuration (labeler-product-package). Convert the 10-digit NDC on the vial label to 11 digits by adding a leading zero to the short segment.
2. Report the NDC in the correct claim field. On the CMS-1500, enter it in the shaded supplemental area of Box 24A for the J3471 line. Use the qualifier N4, then the 11-digit NDC, then UN and the administered quantity. On the 837P, use Loop 2410 (Drug Identification), with LIN03 for the NDC. CTP04 (quantity) and CTP05-1 (unit of measure, UN) carry the amount given.
3. Qualifier for units: use UN (units) as the unit-of-measure qualifier when reporting USP units administered alongside J3471.
4. Verify the NDC against the vial administered, not the purchase order. NDCs can vary between vial sizes and manufacturer batches, so always pull from the label of the vial used.

Verify the Vitrase NDC against the current FDA NDC directory at the time of billing, as package configurations and NDCs can change between manufacturer runs. Never hard-code a single NDC into billing templates without a verification step.

Medicare and Medicaid reimbursement for J3471

Medicare Part B pays for physician-administered drugs, including J3471, under the buy-and-bill model at Average Sales Price plus 6% (ASP+6%). The practice buys Vitrase, administers it, and bills J3471 alongside the drug administration CPT code. Payment follows the current quarter’s limit in the CMS ASP drug pricing files. Those limits update quarterly, so look up the current figure rather than relying on a cached rate.

Medicaid fee-for-service rates for J3471 vary by state and are set independently of Medicare ASP. Managed care organizations under Medicaid contracts may apply their own fee schedules, so load each payer’s rate separately.

Prior authorization requirements for J3471

Medicare Part B does not routinely require prior authorization (PA) for J3471 in the office setting. Medicare Advantage plans, commercial insurers, and Medicaid managed care organizations frequently do. PA rules depend on the payer, the plan year, and the indication, so verify them at each plan renewal.

• Medicare Advantage: many plans require PA for specialty injectables, including J3471. Check the plan’s formulary or authorization portal before administration.
• Commercial insurance: PA is common, particularly for high-dose hypodermoclysis. The clinical note must show that IV access was attempted or contraindicated.
• Medicaid managed care: requirements vary by state and plan. Some plans want step therapy documentation showing that oral fluids were inadequate before approving hypodermoclysis.

A PA request for J3471 typically includes the diagnosis, dose ordered, route of administration, and clinical rationale, such as failed IV access. A request sent without the prescribing provider’s clinical notes is a common reason for PA denial.

How to bill J3471: Administration codes and claim construction

J3471 is a drug code, not a service code. It always appears on a claim alongside a CPT administration code that describes how the drug was given. Our guide to medical billing fundamentals covers the wider claim-construction framework. The J3471-specific steps are below.

1. Select the administration CPT code. For a subcutaneous or intramuscular injection, use CPT 96372. For hypodermoclysis, use the subcutaneous infusion codes, 96369 for the first hour and 96370 for each additional hour. Verify both against the current AMA CPT codebook. The administration code drives the service payment, and J3471 drives the drug payment.
2. Link the diagnosis. The ICD-10-CM code on the claim must reflect the indication for hyaluronidase, not a general injection code. Examples include the condition requiring hypodermoclysis or the drug being co-administered.
3. Add modifiers where applicable. Some payers want modifier JB to confirm subcutaneous administration. Modifier JW reports discarded drug on a separate line, and JZ confirms none was discarded (see the wastage section).
4. Enter the NDC in the supplemental drug information field, as described above.
5. Sequence the claim lines. Place the administration CPT code first, then J3471 on the following line. Some payers apply edits that reject drug codes listed before the administration code.

Documentation requirements to support J3471 claims

Every element below must be in the medical record before J3471 is submitted. Drug codes are audited often, and a missing lot number or unsigned order can trigger a refund demand. Build these checks into the documentation workflow with medical billing compliance protocols, rather than relying on retrospective review.

J3471 wastage and the JW modifier

When Vitrase comes in a single-dose vial and only part of it is given, the unused drug is discarded and reported with modifier JW. CMS enforces its drug wastage policy, so a missing JW line is a documentation deficiency that can surface on audit. Since July 2023, Medicare has also required modifier JZ when no drug from a single-dose container is discarded.

How to report JW wastage for J3471

1. Claim line 1 (drug administered): bill J3471 with units equal to the dose given to the patient. Attach the NDC, UN qualifier, and administered units in the supplemental NDC field.
2. Claim line 2 (discarded drug): bill J3471 with modifier JW. Set units equal to the USP units wasted, which is the vial contents minus the administered amount. Use the same NDC as line 1.
3. Document the wastage in the medical record: note the vial size, the dose administered, and the amount discarded. The Medicare Claims Processing Manual (Chapter 17, Section 40) requires this documentation in the chart to support the JW line.

Payment for JW wastage lines varies by payer. Medicare Part B pays for the wasted drug at the same ASP+6% rate as the administered portion. Some commercial payers do not pay JW lines, so verify payer policy before routinely billing wastage.

Common claim denial reasons for J3471 and how to fix them

Structured denial management workflows cut the revenue lost to J3471 denials. The table maps the most frequent denial triggers to their root causes and fixes. Check code specifics in the AAPC HCPCS code lookup before rebilling.

ICD-10 diagnosis codes commonly paired with J3471

The diagnosis code on a J3471 claim must reflect why hyaluronidase was used, not the patient’s primary chronic condition. A patient with heart failure receiving hypodermoclysis needs the dehydration code, not I50.9, to support medical necessity. Confirm each code in our ICD-10 lookup for coders before the claim goes out.

• E86.0 (Dehydration) and E86.1 (Hypovolemia): commonly used for hypodermoclysis where oral or IV rehydration was not feasible.
• Z79.899 (Other long-term drug therapy): may support adjuvant use when hyaluronidase improves absorption of a concurrent injectable.
• Urography-related codes: for subcutaneous urography, use the ICD-10 code for the urological condition being investigated.

Payer Local Coverage Determinations (LCDs) may restrict covered diagnoses for J3471. Check the relevant Medicare Administrative Contractor (MAC) LCD and any commercial payer policy before assuming a diagnosis will be accepted. Medical spa and aesthetic practices should note that Medicare and most commercial payers do not cover cosmetic indications under J3471.

How Pabau keeps J3471 claims clean

On a typical J3471 claim, the dose lives in the treatment note and the NDC on a vial label. The units sit in a separate billing screen. Each handoff is a chance to retype a number wrong or miss the 999-unit limit.

Pabau, the practice management platform we build, keeps treatment notes, stock records and billing in one system. The dose charted and the vial drawn from stock sit on the same patient record as the invoice. Our claims tools for coders then build the claim from that record, so nobody re-keys the units.

That leaves fewer chances for a unit mismatch or a missing NDC, the two denial triggers this guide keeps returning to.

Stop J3471 denials before they start

Pabau keeps the treatment note, vial stock and claim on one patient record, so J3471 units and NDCs match what was given.

Book a demo

Conclusion

J3471 coding comes down to two checks before the claim leaves: which product was given, and how many units. Get the source right and the code follows. Get the dose right and the split between J3471 and J3472 follows.

The trade-off is a minute at the point of care. Recording the NDC, lot and exact dose during the visit saves a rebill weeks later. Book a demo to see how Pabau carries the charted dose straight through to a clean drug claim.

Continue your research

Need to understand drug code denials in depth? Denial management in healthcare explains how to categorize, track, and appeal claim denials across payer types.

Looking for a clean claim checklist? Clean claim requirements outlines the data elements every drug claim must carry before submission.

Billing a Vitrase dose of 1,000 units or more? HCPCS code J3472 covers the per-1,000-unit ovine code and how it pairs with J3471.

Working with a bovine product instead? HCPCS code J3470 explains billing for Amphadase and Hydase.

Want to see how drug claims move through the system? Revenue cycle management covers the workflow from drug administration to payment posting.

Frequently asked questions